(TAK) Takeda Pharmaceutical - Ratings and Ratios
Gastroenterology, Oncology, Rare Diseases, Immunology, Plasma Therapies
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.3% |
| Value at Risk 5%th | 30.0% |
| Relative Tail Risk | -0.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.28 |
| Alpha | 2.42 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.480 |
| Beta | 0.219 |
| Beta Downside | 0.169 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.25% |
| Mean DD | 9.98% |
| Median DD | 10.03% |
Description: TAK Takeda Pharmaceutical September 29, 2025
Takeda Pharmaceutical Co Ltd (NYSE:TAK) is a Japan-based, globally active pharma company that conducts research, development, manufacturing, marketing, and out-licensing of prescription medicines across several therapeutic categories, including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
The firm’s commercial portfolio features a mix of branded products such as Entyvio (IBD), Gattex/Revestive (short bowel syndrome), EOHILIA (oncology), Alofisel (Crohn’s disease), Takhzyro (hereditary angioedema), and a suite of plasma-derived biologics (e.g., Gammagard, Hyqvia). It also markets oncology agents like Velcade, Iclusig, and Adcetris, as well as CNS drugs such as Trintellix and Vyvanse/Elvanse.
Takeda maintains an extensive network of in-license, out-license, and collaborative agreements with biotech and pharma partners-including BioMarin, GlaxoSmithKline, Seagen, Denali Therapeutics, Arrowhead, and many academic institutions-allowing it to augment its pipeline and access novel modalities such as RNA-targeting and gene-editing technologies.
Key performance indicators (as of FY 2023) show revenue of approximately $31 billion, with R&D spending representing roughly 14 % of sales (~$4.5 billion), reflecting a continued emphasis on innovative biologics. The company’s pipeline contains over 30 late-stage candidates, notably in rare-disease gene therapies and next-generation oncology immunotherapies, which drive future growth expectations. An assumption here is that FY 2023 figures remain representative; any significant currency fluctuation or regulatory outcome could materially alter these metrics.
Sector-wide drivers that influence Takeda’s outlook include the aging global population (increasing demand for chronic-disease treatments), accelerating adoption of advanced therapies (cell, gene, and RNA-based), and pricing pressure from both governments and insurers. Conversely, supply-chain disruptions and heightened competition in biologics pose downside risks.
For a deeper, data-rich assessment of Takeda’s valuation and risk profile, you may find it useful to explore the company’s analytics on ValueRay, where granular financial models and scenario analyses are publicly available.
TAK Stock Overview
| Market Cap in USD | 45,145m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2008-10-27 |
| Return 12m vs S&P 500 | -4.24% |
| Analyst Rating | 4.50 of 5 |
TAK Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 4.69% |
| Yield on Cost 5y | 4.66% |
| Yield CAGR 5y | -2.45% |
| Payout Consistency | 91.9% |
| Payout Ratio | 0.4% |
TAK Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 4.42% |
| CAGR/Max DD Calmar Ratio | 0.19 |
| CAGR/Mean DD Pain Ratio | 0.44 |
| Current Volume | 4641.4k |
| Average Volume | 2928.3k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (33.03b TTM) > 0 and > 6% of Revenue (6% = 265.02b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.68% (prev 14.67%; Δ 3.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 1199.57b > Net Income 33.03b (YES >=105%, WARN >=100%) |
| Net Debt (3963.83b) to EBITDA (813.70b) ratio: 4.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.58b) change vs 12m ago -50.95% (target <= -2.0% for YES) |
| Gross Margin 64.60% (prev 65.95%; Δ -1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.42% (prev 31.20%; Δ -0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.05 (EBITDA TTM 813.70b / Interest Expense TTM 244.32b) >= 6 (WARN >= 3) |
Altman Z'' 0.90
| (A) 0.05 = (Total Current Assets 2920.62b - Total Current Liabilities 2139.66b) / Total Assets 14470.30b |
| (B) 0.08 = Retained Earnings (Balance) 1148.66b / Total Assets 14470.30b |
| (C) 0.02 = EBIT TTM 255.34b / Avg Total Assets 14521.65b |
| (D) 0.16 = Book Value of Equity 1148.66b / Total Liabilities 7338.61b |
| Total Rating: 0.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.12
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 8.59% = 4.29 |
| 3. FCF Margin 22.14% = 5.53 |
| 4. Debt/Equity 0.71 = 2.26 |
| 5. Debt/Ebitda 4.87 = -2.50 |
| 6. ROIC - WACC (= -1.76)% = -2.21 |
| 7. RoE 0.47% = 0.04 |
| 8. Rev. Trend 45.08% = 3.38 |
| 9. EPS Trend 16.47% = 0.82 |
What is the price of TAK shares?
Over the past week, the price has changed by +0.43%, over one month by -0.07%, over three months by -5.10% and over the past year by +8.78%.
Is TAK a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TAK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.7 | 25.5% |
| Analysts Target Price | 17.7 | 25.5% |
| ValueRay Target Price | 14.9 | 6% |
TAK Fundamental Data Overview November 17, 2025
P/E Trailing = 204.1429
P/E Forward = 9.3897
P/S = 0.0102
P/B = 0.9796
P/EG = 0.2924
Beta = 0.028
Revenue TTM = 4417.01b JPY
EBIT TTM = 255.34b JPY
EBITDA TTM = 813.70b JPY
Long Term Debt = 4351.46b JPY (from longTermDebt, last quarter)
Short Term Debt = 293.86b JPY (from shortLongTermDebt, last quarter)
Debt = 5066.16b JPY (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 3963.83b JPY (from netDebt column, last quarter)
Enterprise Value = 11384.49b JPY (6999.81b + Debt 5066.16b - CCE 681.49b)
Interest Coverage Ratio = 1.05 (Ebit TTM 255.34b / Interest Expense TTM 244.32b)
FCF Yield = 8.59% (FCF TTM 977.79b / Enterprise Value 11384.49b)
FCF Margin = 22.14% (FCF TTM 977.79b / Revenue TTM 4417.01b)
Net Margin = 0.75% (Net Income TTM 33.03b / Revenue TTM 4417.01b)
Gross Margin = 64.60% ((Revenue TTM 4417.01b - Cost of Revenue TTM 1563.71b) / Revenue TTM)
Gross Margin QoQ = 65.85% (prev 65.24%)
Tobins Q-Ratio = 0.79 (Enterprise Value 11384.49b / Total Assets 14470.30b)
Interest Expense / Debt = 1.64% (Interest Expense 83.14b / Debt 5066.16b)
Taxrate = 141.6% (out of range, set to none) (39.90b / 28.17b)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.36 (Total Current Assets 2920.62b / Total Current Liabilities 2139.66b)
Debt / Equity = 0.71 (Debt 5066.16b / totalStockholderEquity, last quarter 7130.70b)
Debt / EBITDA = 4.87 (Net Debt 3963.83b / EBITDA 813.70b)
Debt / FCF = 4.05 (Net Debt 3963.83b / FCF TTM 977.79b)
Total Stockholder Equity = 7087.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.23% (Net Income 33.03b / Total Assets 14470.30b)
RoE = 0.47% (Net Income TTM 33.03b / Total Stockholder Equity 7087.33b)
RoCE = 2.23% (EBIT 255.34b / Capital Employed (Equity 7087.33b + L.T.Debt 4351.46b))
RoIC = 2.19% (EBIT 255.34b / (Assets 14470.30b - Curr.Liab 2139.66b - Cash 681.49b))
WACC = 3.96% (E(6999.81b)/V(12065.98b) * Re(6.82%) + (debt cost/tax rate unavailable))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -29.41%
[DCF Debug] Terminal Value 75.80% ; FCFE base≈845.77b ; Y1≈723.96b ; Y5≈562.74b
Fair Price DCF = 3255 (DCF Value 10282.25b / Shares Outstanding 3.16b; 5y FCF grow -17.51% → 3.0% )
EPS Correlation: 16.47 | EPS CAGR: -0.74% | SUE: -0.00 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 0.54% | SUE: -0.04 | # QB: 0
Additional Sources for TAK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle